Research programme: autoimmune disorder therapies - VLST Corporation
Latest Information Update: 25 Jun 2014
At a glance
- Originator VLST Corporation
- Class
- Mechanism of Action Cytokine inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 25 Jun 2014 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 25 Jun 2014 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 18 Aug 2008 Preclinical trials in Autoimmune disorders in USA (unspecified route)